Skip to content
The Chat Archive
Human-written demonstration (OpenAssistant volunteers)· OpenAssistant (human-written) OpenAssistant Conversations (oasst2)

explain de novo lipogenesis

In OpenAssistant data, “assistant” turns were written by human volunteers as demonstrations. They are not model outputs.
  1. User

    explain de novo lipogenesis

  2. Assistant

    De novo lipogenesis (DNL) is a metabolic process in which the body produces new fatty acids from non-fat sources, such as carbohydrates, protein, and alcohol. This process primarily occurs in the liver and adipose (fat) tissues, and is regulated by several enzymes and hormones.

    During DNL, the body converts excess dietary carbohydrates and protein into fatty acids through a series of biochemical reactions. The first step of DNL is the conversion of glucose into acetyl-CoA through a process called glycolysis. Acetyl-CoA is then converted into malonyl-CoA by the enzyme acetyl-CoA carboxylase (ACC). Malonyl-CoA is used as a substrate by the fatty acid synthase (FAS) complex to synthesize fatty acids, which are then incorporated into triglycerides and stored in adipose tissue or used as an energy source.

    DNL is regulated by several hormones, including insulin, glucagon, and leptin. Insulin promotes DNL by stimulating the uptake of glucose and amino acids, and activating ACC and FAS enzymes. Conversely, glucagon and leptin inhibit DNL by inhibiting ACC and FAS enzymes and promoting the breakdown of stored fats.

    Although DNL is an important metabolic process, excessive DNL can lead to the accumulation of fat in the liver and contribute to the development of metabolic diseases such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).

  3. User

    How does alcohol contribute to a fatty liver?

  4. Assistant

    Alcohol contributes to fatty liver through various mechanisms. Alcohol increases the NADH/NAD+ ratio, which inhibits fatty acid oxidation and tricarboxylic acid cycle reactions, leading to fat accumulation in the liver (Purohit 2009; You 2004). Alcohol also increases the activity of sterol regulatory element-binding protein-1 (SREBP-1), plasminogen activator inhibitor-1 (PAI-1), and early growth response-1, while decreasing peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activity, which promotes lipogenesis and inhibits fat oxidation (Liu 2014; You 2004). Alcohol also activates the innate immune system, leading to Kupffer cell-derived tumor necrosis factor-alpha (TNF-alpha) overproduction, which upregulates SREBP-1 and PAI-1 activity (Liu 2014). Chronic alcohol consumption also retards lipophagy, which exacerbates steatosis (Yang 2019). The papers suggest that PPAR-alpha agonists, adiponectin, interleukin-6, and carvedilol may attenuate alcoholic fatty liver by upregulating PPAR-alpha and insulin signaling pathways while downregulating SREBP-1 activity and suppressing TNF-alpha production (Purohit 2009; You 2004; Liu 2014).

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.